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A B S T R A C T
The complement-fixation test (CFT) permits low-cost screening of serum samples for different agents
within a single assay, and is a useful tool for the serological diagnosis of acute respiratory infections.
This study evaluated the automated Seramat CFT system with 160 paired serum samples taken from
80 patients with acute respiratory infection in comparison with in-house CFTs against a panel of agents,
including influenza A and B, adenovirus, respiratory syncitial virus, cytomegalovirus, Mycoplasma
pneumoniae, Coxiella burnetti and Chlamydia spp., and in comparison with indirect immunofluorescence
(IIF) against Legionella pneumophila. Overall, the Seramat system identified 75 (88.2%) of the 85
seroconversions recognised by in-house CFTs or IIF. In comparison to the in-house CFTs, the correlation
was 89.2% (66 ⁄ 74). For L. pneumophila, the Seramat system detected nine (81.8%) of the 11 cases
diagnosed by IIF. The Seramat system also identified eight additional seroconversions that were not
detected by the in-house assays; none of these seroconversions was detected by the in-house assay on
retesting. The Seramat system represents a significant technical improvement that may enable many
clinical laboratories to use the CFT as a routine diagnostic tool.
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I N T R O D U C T I O N
Viral and bacterial isolation from respiratory
secretions are reference methods for the diagnosis
of acute respiratory infections (ARIs). In addition,
methods for direct detection of viral antigens in
such samples provide rapid diagnosis of some
of these infections. However, neither isolation
nor antigen-detection procedures can provide
the clinical laboratory with tools suitable for the
routine diagnosis of all the agents involved in the
aetiology of ARIs, especially with regard to
atypical bacteria such as Mycoplasma pneumoniae,
Chlamydia psittaci, Chlamydia pneumoniae, Coxiella
burnetti and Legionella pneumophila. Isolation of
these bacteria from clinical samples is difficult
to achieve, and antigen-detection tests do not
provide the specificity required for routine diag-
nostic use. Molecular assays for detecting the
genomes of most of the bacterial and viral agents
involved in ARIs have also been developed and
shown to be useful for diagnosis [1–3], but such
assays have not yet been standardised for routine
use in the clinical setting.
Detection of the specific antibody response is,
meanwhile, a useful alternative for the diagnosis
of ARI, and can be performed by different
techniques. Among these, the complement-fix-
ation test (CFT) has been used for decades and
represents the most practical approach because it
permits the screening of samples for many differ-
ent agents within a single assay. In addition, the
CFT has shown good diagnostic performance in
comparison with other assays, especially for
M. pneumoniae [4–6], Cox. burnetti [7] and certain
viruses [8], and has been recognised as a reference
method for the diagnosis of ARI caused by
M. pneumoniae and Cox. burnetti [9–11]. Finally,
but no less importantly, the cost of CFT reagents
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is low. However, the CFT is time-consuming,
difficult to standardise, and must be performed
by highly qualified personnel with strict quality
control. These problems, which hamper the use of
CFT in many clinical laboratories, could be
eliminated by automation of the technique.
Recently, an automated system (Seramat) for
detecting complement-fixation antibody against
different viral and bacterial agents has been
developed. The system includes standardised
reagents, quality control materials and an auto-
mated device to perform the assay. The present
paper describes the results obtained by Seramat
with a panel of serum samples from patients with
ARI that showed seroconversion to different
bacterial and viral antigens when examined by
an in-house CFT.
M A T E R I A L S A N D M E T H O D S
A retrospective panel of 160 paired serum samples, taken from
80 patients with ARI, was used in the study. All samples were
stored at )20 C until used in the present study.
Antibodies to influenza A virus (IAV), influenza B virus
(IBV), adenoviruses (ADV, group antigen), respiratory synci-
tial virus (RSV), human cytomegalovirus (CMV), M. pneumo-
niae, Cox. burnetti and Chlamydia spp. (group antigen, including
C. psittaci, C. pneumoniae and C. trachomatis) were determined
in all samples by an in-house CFT assay. IgG antibody to
L. pneumophila was also determined with an indirect immuno-
fluorescence (IIF) assay.
The in-house CFT was performed by a standard proce-
dure [12] with commercially available antigens (Virion-
Serion, Wu¨rzburg, Germany). Samples from children were
titrated from 1 : 8; those from adults were titrated from
1 : 64. The IIF assay for IgG antibody to L. pneumophila was
performed as described elsewhere [13]. In both assays,
seroconversion was defined as a change from a negative to
a positive result, or a four-fold or higher rise between acute
and convalescent sera.
The automated CFT method (Seramat system; Diesse,
Monteriggioni, Italy) was used to quantify antibody against
the agents listed above in all the serum samples included in the
investigation. The Seramat system comprises an automated
processor and diagnostic kits. The kits include freeze-dried or
liquid antigens, ready-to-use complement and haemolysin
preparations, and stabilised (6-month shelf-life) erythrocytes.
After inactivation at 56 C for 30 min, the undiluted serum
samples are placed in the processor, which performs all the
reaction steps automatically. Reading of results is carried out
by evaluation of the haemolysis kinetics, measured every 20 s
by turbidimetry during the last 7 min of the incubation period
with the haemolysis mixture. Strongly positive samples are
automatically retested in an over-range cycle, and anti-com-
plementary activity of samples and antigens is also automat-
ically determined on the corresponding control positions.
Results are presented as endpoint dilution titres, which are
calculated by dedicated software, and can be directly com-
pared with titres obtained with conventional CFT protocols.
The system can perform c. 140 determinations in a 5-h session.
Seroconversion was defined as a change from negative to
positive results, or a four-fold or higher rise between acute and
convalescent sera.
R E S U L T S
With use of the in-house CFTs and commercial IIF
assay, seroconversion for antibody against a
single agent was detected in 76 cases. The agents
involved were IAV (17 cases), IBV (seven cases),
ADV (five cases), RSV (six cases), CMV (five
cases), M. pneumoniae (nine cases), Cox. burnetti
(six cases), Chlamydia spp. (12 cases), and
L. pneumophila (nine cases). In addition, serocon-
version for antibody against two or more
agents was detected in four other cases (IAV +
ADV + CMV; IAV + L. pneumophila; IBV +
M. pneumoniae; and CMV + L. pneumophila), so
that, in total, 85 seroconversions were documented.
Overall, the Seramat system identified 75
(88.2%) of the 85 seroconversions recognised
(Table 1). For agents recognised by the in-house
CFT, the correlation rose to 89.2% (66 of 74
seroconversions detected). Among cases of
L. pneumophila infection, with seroconversion
demonstrated by IIF, the Seramat system detected
nine (81.8%) of 11 cases. The correlation between
the Seramat system and in-house CFT results was
100% for ADV, M. pneumoniae and Chlamydia spp.
infections.
Table 2 lists the ten identified seroconversions
that were not recognised by the Seramat system.
However, the Seramat system recognised eight
additional seroconversions (Table 3) that were not
detected by the in-house CFTs, thus resulting in
Table 1. Comparison of results obtained by the Seramat
system with seroconversions recognised by in-house com-
plement-fixation tests (CFTs) or indirect immunofluores-
cence assays
Antigen
No. of
seroconversionsa
Seroconversions in
Seramat system (%)
IAV 19 18 (94.7)
IBV 8 6 (75)
ADV 6 6 (100)
RSV 6 5 (83.3)
M. pneumoniae 10 10 (100)
Cox. burnetti 6 4 (66.7)
Chlamydia spp. 12 12 (100)
CMV 7 5 (71.4)
L. pneumophila 11 9 (81.8)
Total 85 75 (88.2)
aAll agents diagnosed by CFT, except L. pneumophila (IIF).
IAV, influenza A virus; IBV, influenza B virus; ADV, adenovirus; RSV, respiratory
syncitial virus; CMV, cytomegalovirus.
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detection of further cases of multiple infection.
None of these seroconversions was detected by
the in-house CFT on retesting.
D I S C U S S I O N
Despite the potential of CFT as a routine assay for
diagnosis of patients with ARI in the clinical
setting, the lack of standardised reagents and
automated devices for sample processing have
hampered the use of this technique in clinical
laboratories. Since other diagnostic procedures,
such as isolation of the agent or direct antigen
detection, are often difficult to use in routine
virology, the aetiology of most cases of ARI
admitted to hospitals remains unknown. Thus,
for example, in Spain during 2000, only 466 cases
of atypical pneumonia of known aetiology (119
viral and 347 bacterial infections) were recorded,
a figure that is likely to represent only a minor
part of the total cases admitted to Spanish
hospitals during that year (Spanish Ministry of
Health, unpublished results). With the single
exception of the detection of L. pneumophila
antigen in urine samples, which accounted for
24% of the bacterial infections reported, most
cases were diagnosed by antibody tests. The CFT
was often used for diagnosis of viral infections
(77%), but not for the identification of cases
caused by bacteria, which required the use of
many different IIF, enzyme immunoassay and
agglutination tests.
The Seramat CFT assay evaluated in the pre-
sent investigation detected almost 90% of the
seroconversions included in the panel with an
automated protocol that only required manual
heat inactivation of the serum samples. The
correlation was high for all the agents studied,
including infections by L. pneumophila that were
not initially diagnosed by CFT, but by IIF. The ten
discrepant results (i.e., no seroconversion detec-
ted by Seramat) did not correspond to any
particular agent (Table 2). Eight new seroconver-
sions against four different antigens were detec-
ted by the Seramat system. These seroconversions
were not identified initially by the in-house
CFT and IIF assays, and were not detected on
retesting.
The performance of diagnostic kits in routine
conditions must be ensured by the manufacturer
Table 2. Samples showing seroconversion by in-house
complement-fixation tests (CFTs) or indirect immunofluo-
rescence (IIF) assays that were not detected by the Seramat
system
Sample Antigen
Titre by in-house
methodsa
Titre by Seramat
system
760 IAV 128 32
864 512 64
1548 IBV < 8 8
1618 64 8
243 IBV 16 16
244 64 32
971 RSV < 8 16
1149 32 32
1636 Cox. burnetti < 64 128
1637 256 128
1010 Cox. burnetti < 64 16
1155 256 32
1281 CMV 32 64
1282 > 128 128
1850 CMV 8 8
1851 32 16
600 L. pneumophila < 64 < 8
601 128 8
2491 L. pneumophila < 64 < 8
2492 128 8
aAll agents diagnosed by CFT, except L. pneumophila (IIF).
IAV, influenza A virus; IBV, influenza B virus; RSV, respiratory syncitial virus;
CMV, cytomegalovirus.
Table 3. Samples showing serocon-
version by the Seramat system that
were not detected by in-house com-
plement-fixation tests (CFT) or indi-
rect immunofluorescence (IIF) assays
Sample
number Original diagnosis Antigen
Titre by
Seramat system
Titre by
in-house CFT
654 Coxiella IAV 8 16
761 32 32
524 Mycoplasma RSV < 8 32
525 16 32
549 RSV Chlamydia < 8 < 8
873 64 < 8
1206 Coxiella Chlamydia 8 < 8
1313 32 < 8
128 IAV, ADV, CMV Chlamydia < 8 < 8
1233 32 8
1469 L. pneumophila Chlamydia < 8 < 8
1470 32 8
1869 Chlamydia CMV 8 32
1870 32 32
2006 Chlamydia CMV 16 16
1074 64 32
IAV, influenza A virus; IAV, influenza A virus; ADV, adenovirus; CMV, cytomegalovirus; RSV, respiratory
syncitial virus.
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through proper standardisation of the different
lots produced. In the CFT, uniform quality of the
antigens is essential in order to satisfy this
important requirement. During the present eval-
uation, different lots of RSV and Cox. burnetti
antigens had to be tested before optimal results
could be obtained for the panel of samples.
Differences were especially strong with the two
lots of Cox. burnetti antigen tested, which detected
none of seven, and four of six seroconversions,
respectively (data not shown). Testing of the
samples with the Seramat reagents by a manual
procedure confirmed that these differences arose
from the different quality of the antigens, but not
from the other reagents.
Overall, the Seramat assay results were very
close to those of the in-house assays with this
particular panel of samples, and this finding
would support its routine use for diagnostic
purposes. Significant batch-to-batch performance
differences were, however, found for some anti-
gens. A batch release system for Seramat CFT kits,
based on testing of suitable seroconversion panels,
is recommended in order to monitor performance
and ensure adequate lot-to-lot uniformity. Since
the current European directive for quality control
of diagnostic reagents does not include most of the
main agents involved in ARI, development of such
reference material would be of major interest.
In conclusion, the Seramat system represents
a significant technical improvement that may
enable many clinical laboratories to incorporate
the CFT as a routine diagnostic tool. ARI is an
important application for the method, but other
common clinical conditions, such as fever of
unknown origin and infectious mononucleosis-
like syndromes, could also benefit from wider use
of the CFT assay in the clinical setting. Besides
automation, standardisation and quality control
will always be essential issues in relation to
routine use of the CFT for diagnostic purposes,
so that the provision of quality control materials
could be considered as an important target for the
immediate future.
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